Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Curex vs NiceRx

Two GLP-1 desks, one scoreboard. We put Curex and NiceRx head-to-head on the published Brief Score — the same six factors, scored the same way, no pay-to-win placement.

No. 13 · Grade B

Curex

Visit Curex Full brief →
vs
No. 12 · Grade B

NiceRx

Visit NiceRx Full brief →

The verdict

Too close to call on the Brief Score.

Curex and NiceRx are level at 86/100. The scores won't separate them, so the pick comes down to fit: Curex for readers who want one predictable price across sema and tirz from an accredited, nationwide desk. NiceRx for readers who want a longer-tenured, accredited name over an unknown newcomer.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
85
85
Supply Reliability
85
86
Transparency
87
87
Access Breadth
90
87
Clinical Oversight
86
86
Track Record
81
84
CurexBrief Score 86 · 86NiceRx

Price, coverage & the tracker

CurexNiceRx
Brief Score86/100 (B)86/100 (B)
Semaglutide$199/mo$199/mo
Tirzepatide$199/mo$299/mo
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
On the trackerStableprice stableStableprice stable

Curex: Flat $199 on both molecules; LegitScript-certified and nationwide.

NiceRx: $199 sema / $299 tirz nationwide; LegitScript-certified, established operator.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.